Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
Zhe Jiang, … , Charles M. Perou, Eldad Zacksenhaus
Zhe Jiang, … , Charles M. Perou, Eldad Zacksenhaus
Published August 2, 2010
Citation Information: J Clin Invest. 2010;120(9):3296-3309. https://doi.org/10.1172/JCI41490.
View: Text | PDF
Research Article Oncology

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status

  • Text
  • PDF
Abstract

Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized by distinct histology, gene expression patterns, and genetic alterations. The tumor suppressor gene retinoblastoma 1 (RB1) is frequently lost in both luminal-B and triple-negative tumor (TNT; i.e., estrogen receptor–, progesterone receptor–, and human epidermal growth factor receptor 2–negative) breast cancer subtypes. However, a causal role for RB1 loss in different subtypes remains undefined. Here we report that deletion of Rb alone or together with its relative p107 in mouse mammary stem/bipotent progenitor cells induced focal acinar hyperplasia with squamous metaplasia. These lesions progressed into histologically diverse, transplantable mammary tumors with features of either luminal-B or TNT subtypes. The TNTs included basal-like tumors as well as tumors that exhibited epithelial-to-mesenchymal transition (EMT). The EMT-type tumors and a subset of the basal-like tumors, but not luminal-B–like tumors, expressed mutant forms of the tumor suppressor p53. Accordingly, targeted deletion of both Rb and p53 in stem/bipotent progenitors led to histologically uniform, aggressive, EMT-type tumors. Reintroduction of Rb into these tumor cells suppressed growth in vitro and tumor formation in vivo. These results establish a causal role for Rb loss in breast cancer in mice and demonstrate that cooperating oncogenic events, such as mutations in p53, dictate tumor subtype after Rb inactivation.

Authors

Zhe Jiang, Tao Deng, Robert Jones, Huiqin Li, Jason I. Herschkowitz, Jeff C. Liu, Victor J. Weigman, Ming-Sound Tsao, Timothy F. Lane, Charles M. Perou, Eldad Zacksenhaus

×

Figure 4

MMTV-Cre:Rbfl/fl and MMTV-Cre:Rbfl/fl:p107–/– mice develop transplantable mammary tumors.

Options: View larger image (or click on image) Download as PowerPoint
MMTV-Cre:Rbfl/fl and MMTV-Cre:Rbfl/fl:p107–/– mice develop transplantabl...
(A) Dissected MMTV-Cre:Rbfl/fl:p107–/– female with 2 large tumors in mammary gland nos. 4 and 5 (arrows). (B) Tumor-free curve for a cohort of 22 RbΔfl mice (2 MMTV-Cre:Rbfl/fl:p107+/+, 12 MMTV-Cre:Rbfl/fl:p107–/– and 8 MMTV-Cre:Rbfl/fl:p107+/–) and 20 control (without MMTV-Cre) littermates. (C) Complex PCR analysis with the 3 primers. Lane 1, Rb+/+ mouse tail; lane 2, Rbfl/fl mouse tail; lane 3, MMTV-CreNLST:Rbfl/fl:p107–/– mammary tumor; lane 4, MMTV-CreD:Rbfl/+:p107+/– heterozygote mammary tumor, demonstrating LOH at the Rb locus. Lanes were run on the same gel but were noncontiguous (white line). (D–G) H&E staining of representative RbΔfl tumors and pulmonary metastasis. (D) Tumor 2, adenosquamous carcinoma. (E) Tumor 4, solid adenocarcinoma with comedo patterns. (F) Tumor 9, adenocarcinoma with cystic changes. (G) Pulmonary metastasis in MMTV-Cre:Rbfl/fl:p107–/– mutant shown in F. Note glandular tumors with histology similar to the original tumor. Inset: low-magnification image of the pulmonary metastasis (right; normal lung tissue on left). (H and I) CD24-CD49f flow cytometry profiles of Lin– control mammary gland (H) and RbΔfl tumor (I). (J) Mean Lin–CD24+CD49f+ cells in RbΔfl mammary tumors (n = 4) relative to Lin– mammary epithelial cells from control littermates (n = 6). P < 0.01. (K–N) RbΔfl mammary tumor cells were transplantable. (K) Secondary RbΔfl tumorspheres cultured for 2 weeks. (L) A Rag1–/– female mouse with secondary RbΔfl mammary tumors arising after transplantation of 10,000 and 1,000 tumorsphere cells into the right and left, respectively, of mammary gland no. 4. (M) Primary, poorly differentiated adenocarcinoma. (N) Secondary tumor after transplantation of tumorsphere cells derived from the tumor in M. Original magnification, ×200 (D–F); ×400 (G, M, and N); ×100 (G, inset); ×20 (K).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts